Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression

6 Dec 2023

Abstract excerpt

Background: Recent data suggests that HER2-targeted treatment is efficacious in urothelial carcinoma (UC). We investigated the genomic, transcriptomic, and immune landscapes and clinical outcomes in UC segmented by ERBB2 expression. Methods: NextGen DNA/RNA sequencing was performed for 4743 UC tumors. A total of 3% (124/4125) of tumors had HER2 IHC and whole transcriptome sequencing (WTS) data. ERRB2-high and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Ferroptosis and cancer prognosis
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38136267
DOI: 10.3390/cancers15245721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 ExpressionPMID 38136267Read ↗

Defining biologically directed therapy target signatures in urothelial carcinoma: A transcriptomic framework for precision therapySemantic proximity Read ↗

Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper Tract and Bladder Urothelial CarcinomaSemantic proximity Read ↗

Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.Semantic proximity Read ↗

TROP2 expression is associated with early stage and favorable prognosis in Upper tract urothelial carcinomaSemantic proximity Read ↗

Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.Semantic proximity Read ↗

Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapySemantic proximity Read ↗

Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.Semantic proximity Read ↗

Molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinomaSemantic proximity Read ↗

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.Semantic proximity Read ↗

Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.Semantic proximity Read ↗

Genomic Characterization of Upper Tract Urothelial Carcinoma.Semantic proximity Read ↗

The genomic and transcriptomic landscape of metastastic urothelial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.